Risk Factors of Porphyria Cutanea Tarda (PCT)

Porphyria Cutanea Tarda Clinical Trial

Official title:

“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00213772
• Other study ID #: 2030
• Status: Completed
• Phase: N/A
• First received: September 13, 2005
• Last updated: September 13, 2005
• Start date: May 1999

Study information

• Verified date: September 2005
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Observational

Clinical Trial Summary

Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.

Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 280
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Porphyria cutanea tarda /HCV negative Porphyria cutanea tarda/ HCV positive HCV positive HCV negative controls

Study Design

Observational Model: Case Control, Time Perspective: Longitudinal

Related Conditions & MeSH terms

• Porphyria Cutanea Tarda
• Porphyria, Erythropoietic
• Porphyrias

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France